搜尋
Blueprint Medicines Corp
BPMC添加自選
129.460USD
0.0000.00%
交易中 （美東）報價延遲15分鐘
8.36B總市值
虧損本益比TTM
關於 Blueprint Medicines Corp 公司
Blueprint Medicines Corporation 是一家全球精準治療公司，正在過敏/炎症和腫瘤/血液學兩個領域發明改變生命的藥物。該公司向美國和歐洲的患者提供其獲批的藥物，包括 AYVAKIT/AYVAKYT (avapritinib) 和 GAVRETO (pralsetinib)，並在全球範圍內推進針對系統性肥大細胞增多症 (SM)、肺癌、乳腺癌和其他基因組定義的癌症以及癌症免疫療法的多個項目。該公司的產品線還包括 Elenestinib (BLU-263) (KIT)、AYVAKIT (avapritinib) (KIT)、野生型 KIT 研究項目、GAVRETO (pralsetinib) (RET)、BLU-945 (EGFR)、BLU-525 (EGFR)、BLU-451 (EGFR 外顯子 20 插入)、BLU-222 (CDK2)、AYVAKIT (PDGFRA)、GAVRETO (RET)、BLU-222 (CDK2) 和 BLU-852 (MAP4K1)。該公司正在開發一種口服、有效且高選擇性的試驗性 KIT 抑制劑 Elenestinib (BLU-263)，用於治療惰性 SM 和其他肥大細胞疾病。
Blueprint Medicines Corp簡介
公司代碼BPMC
公司名稱Blueprint Medicines Corp
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
員工數量649
證券類型Ordinary Share
年結日Apr 30
公司地址45 Sidney Street
城市CAMBRIDGE
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編02139
電話16173747580
網址https://www.blueprintmedicines.com/
公司代碼BPMC
上市日期Apr 30, 2015
CEOMs. Kathryn D (Kate) Haviland
Blueprint Medicines Corp公司高管
名稱
名稱/職務
職務
持股
持股變動
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+0.03%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+0.10%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-0.10%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-0.08%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-0.51%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
Mr. Michael J. Tolpa
Mr. Michael J. Tolpa
Director
Director
--
--
Ms. Debra Durso-Bumpus
Ms. Debra Durso-Bumpus
Chief People Officer
Chief People Officer
--
--
Dr. Philina Lee, Ph.D.
Dr. Philina Lee, Ph.D.
Chief Commercial Officer
Chief Commercial Officer
--
-100.00%
Ms. Jenna Cohen
Ms. Jenna Cohen
Vice President and Head, Investor Relations
Vice President and Head, Investor Relations
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Kathryn D (Kate) Haviland
Ms. Kathryn D (Kate) Haviland
President, Chief Executive Officer
President, Chief Executive Officer
73.23K
+0.03%
Dr. Fouad Namouni, M.D.
Dr. Fouad Namouni, M.D.
President - Research and Development
President - Research and Development
31.96K
+0.10%
Ms. Christina Rossi
Ms. Christina Rossi
Chief Operating Officer
Chief Operating Officer
19.39K
-0.10%
Mr. Percy H. Carter, Ph.D.
Mr. Percy H. Carter, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
16.43K
-0.08%
Mr. Michael Landsittel
Mr. Michael Landsittel
Chief Financial Officer
Chief Financial Officer
13.43K
-0.51%
Ms. Ariel Hurley, CPA
Ms. Ariel Hurley, CPA
Senior Vice President - Finance, Principal Accounting Officer
Senior Vice President - Finance, Principal Accounting Officer
11.89K
--
常見問題
Blueprint Medicines Corp的前五大股東是誰？
Blueprint Medicines Corp的前五大股東如下：Ms. Kathryn D (Kate) Haviland
有多少機構持有Blueprint Medicines Corp(BPMC)的股份？
截至2025Q2，共有701家機構持有Blueprint Medicines Corp的股份，合計持有的股份價值約為68.81M，占公司總股份的106.41% 。與2025Q1相比，機構持股有所增加，增幅為-3220329.00。
哪個業務部門對Blueprint Medicines Corp的收入貢獻最大？
在2025Q2，Product revenue業務部門對Blueprint Medicines Corp的收入貢獻最大，創收128.18M，占總收入的100.00% 。
